South America Gene Therapy Market Reached USD 722.6 Billion in 2024 – Brazil Captured 56.7% Share

The South America gene therapy market is rapidly gaining traction as a significant part of the global biopharma landscape. In 2024, the regional market reached USD 722.6billion, showing strong demand and expanding research activities.

Forecasts indicate that this market will continue its steep rise, growing at a CAGR of approximately 25.26% through 2032, potentially surpassing USD 2,558.87 billion by the end of the decade.

This article explores the latest statistics, key regional insights, and how South America compares with North America and other global markets in gene therapy.

South America Gene Therapy: Numbers that Matter

South America’s gene therapy sector is emerging quickly, underpinned by increasing clinical development and biotech investment.

Key Market Highlights (2024):

• Market valued at USD 722.6 billion
• Expected to grow to USD 2,558.87 billion by 2032
• Estimated CAGR of ~25.26% (2025–2032)
• Viral vector therapies contribute the largest revenue share

These trends reflect a growing adoption of gene therapy technologies, especially in oncology and genetic disease treatment pipelines.

Global Market Size:

The global gene therapy market size is calculated at USD 9.5 in 2024, grew to USD 11.4 billion in 2025, and is projected to reach around USD 58.87 billion by 2034. The market is expanding at a CAGR of 20% between 2025 and 2034.

Our experts provide regional insights, growth stats, and competitor analysis to help you stay ahead.
Purchase the full report today and make informed moves: https://www.towardshealthcare.com/checkout/5804

Country-Level Shares Across South America

Within the broader South & Central American cell and gene therapy landscape, country activity varies, with clear leadership and emerging hubs.

Top Regional Insights:

• Brazil accounts for about 56.7% of the regional market
• Argentina, Chile, and other countries contribute through early-stage research and collaboration
• Brazil’s dominance is driven by stronger clinical research infrastructure and biotech investment

This sub‑regional division demonstrates how Brazil currently anchors gene therapy growth in South America, while other markets are steadily building capacity.

North America: Still the Largest Gene Therapy Market

Take a look before making a decision; our sample is customized as per your business needs.
Download it for free today: https://www.towardshealthcare.com/download-sample/5804

While South America expands rapidly, North America remains the dominant region in global gene therapy.

Market Facts for North America:

• North America held over 45% of global gene therapy market share in 2024
• Significant growth stems from extensive R&D investments, healthcare infrastructure, and favorable policy environments
• The United States is a key growth driver in cancer and rare disease gene therapy, supported by robust regulatory frameworks and funding

This strong performance in North America sets a benchmark while global gene therapy adoption accelerates.

What’s Driving Growth in South America?

Several trends have pushed South America’s gene therapy market forward:

Rising Disease Burden

• Chronic and genetic diseases in the region are increasing demand for novel therapies
• Gene therapies are seen as potential long‑term treatment solutions

Clinical Trial Expansion

• A growing number of gene therapy clinical trials are taking place across South American countries
• This reflects both academic and industrial interest in advanced therapeutic modalities

Strategic Investments

• Biotech firms and multinational collaborations are investing in:
  • Process development
  • Biomanufacturing capabilities
  • Regulatory support networks
  • Research and clinical partnerships

These factors are creating a stronger ecosystem for gene therapy development and eventual commercialization.

South America vs. Global Gene Therapy Landscape

Key Regional Comparison

• South America: USD 722.6 billion in 2024 with strong CAGR through 2032
• North America: Over 45% global share in 2024, largest single regional contributor
• Latin America (including South America): Consistent clinical trial growth

Though absolute values in South America currently lag behind North America, the pace of growth and increasing clinical activity position the region as an emerging gene therapy hub with long‑term potential.

Factors Shaping South America’s Gene Therapy Market

Two major trends are notable:

• Viral Vector Dominance
  Viral vectors continue to generate the largest share of gene therapy revenue in the region, particularly in treatments targeting oncology and rare disorders.
• Expanding Country Footprint
  While Brazil leads the market, other nations — including Argentina and Chile — are expanding research capabilities and biotechnology engagement.

Bullet Summary: South America Gene Therapy at a Glance

• South America’s gene therapy market reached USD 722.6 billion in 2024
• Projected to grow to USD 2,558.87 billion by 2032
• Estimated CAGR at ~25.26% through 2032
• Brazil holds the largest regional share (~56.7%)
• Viral vector therapies lead in revenue generation
• Emerging research and clinical expansion across multiple countries

Conclusion

The South America Gene Therapy Market has moved beyond early‑stage growth into a fast‑emerging regional force within the global biotech arena. With strong growth projections, increasing clinical research, and expanding infrastructure, South America is becoming a noteworthy contributor to the future of gene therapy.

While North America currently dominates global share, South America’s rapid trajectory and investment activity set the stage for continued expansion. The region’s gene therapy landscape is one to watch; not just for local impact, but for global innovation and therapeutic advancement.